1. Home
  2. ALT vs BUI Comparison

ALT vs BUI Comparison

Compare ALT & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • BUI
  • Stock Information
  • Founded
  • ALT 1997
  • BUI 2011
  • Country
  • ALT United States
  • BUI United States
  • Employees
  • ALT 59
  • BUI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • BUI Trusts Except Educational Religious and Charitable
  • Sector
  • ALT Health Care
  • BUI Finance
  • Exchange
  • ALT Nasdaq
  • BUI Nasdaq
  • Market Cap
  • ALT 348.6M
  • BUI 600.6M
  • IPO Year
  • ALT N/A
  • BUI N/A
  • Fundamental
  • Price
  • ALT $4.14
  • BUI $26.68
  • Analyst Decision
  • ALT Strong Buy
  • BUI
  • Analyst Count
  • ALT 7
  • BUI 0
  • Target Price
  • ALT $16.50
  • BUI N/A
  • AVG Volume (30 Days)
  • ALT 2.8M
  • BUI 59.8K
  • Earning Date
  • ALT 11-11-2025
  • BUI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • BUI 6.79%
  • EPS Growth
  • ALT N/A
  • BUI N/A
  • EPS
  • ALT N/A
  • BUI 2.75
  • Revenue
  • ALT $20,000.00
  • BUI N/A
  • Revenue This Year
  • ALT N/A
  • BUI N/A
  • Revenue Next Year
  • ALT N/A
  • BUI N/A
  • P/E Ratio
  • ALT N/A
  • BUI $7.77
  • Revenue Growth
  • ALT N/A
  • BUI N/A
  • 52 Week Low
  • ALT $2.90
  • BUI $18.73
  • 52 Week High
  • ALT $11.16
  • BUI $24.22
  • Technical
  • Relative Strength Index (RSI)
  • ALT 59.34
  • BUI 52.48
  • Support Level
  • ALT $3.83
  • BUI $26.31
  • Resistance Level
  • ALT $4.10
  • BUI $26.77
  • Average True Range (ATR)
  • ALT 0.18
  • BUI 0.35
  • MACD
  • ALT 0.01
  • BUI -0.02
  • Stochastic Oscillator
  • ALT 88.63
  • BUI 36.27

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About BUI BlackRock Utility Infrastructure & Power Opportunities Trust

BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.

Share on Social Networks: